Clinical Data In patients with moderate to severe ulcerative colitis, histologic improvement was greater with ozanimod 1 mg versus placebo at weeks 8 and 32.  A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo.  TOUCHSTONE met its primary endpoint and secondary endpoints of safety and efficacy with statistical significance for patients on the 1 mg dose of ozanimod versus placebo.